<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882307</url>
  </required_header>
  <id_info>
    <org_study_id>hhayam</org_study_id>
    <nct_id>NCT03882307</nct_id>
  </id_info>
  <brief_title>Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera</brief_title>
  <official_title>Association of Serum Interleukin -6 and Transforming Growth Factor Beta Levels With Response to Antiviral Therapy for Chronic Hepatitis c Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality
      owing to progression of a high percentage (85%) of HCV infected patients to chronic
      hepatitis, which might lead to the development of liver cirrhosis or hepato cellular
      carcinoma..

      Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population
      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, second-generation direct-acting antiviral agents have been used for chronic
      hepatitis C treatment. The association of sofosbuvir with daclatasvir or simeprevir , with or
      without ribavirin , directly inhibits viral replication .

      Sofosbuvir (400 mg once per day) and daclatasvir (60mg once per day) or simeprevir (150 mg
      once per day) for 3 months treatment regimens.

      Sofosbuvir-based antiviral therapy guarantees efficacy in HCV eradication in approximately
      90% of cases and is associated with mild to moderate adverse effects.

      Overall, studies describe an increase in serum cytokine levels in chronic hepatitis C
      patients, when compared with healthy individuals. ,interleukin-6(IL-6) is produced mainly by
      kupffer cells and induces the production of the acute phase proteins, C-reactive protein and
      haptoglobin .

      Previous studies reported that serum Interleukin-6 levels were increased, compared with
      healthy individuals, in patients with some liver diseases.Previous results suggest that
      baseline levels of Interleukin, as well as their decrease during treatment .Transforming
      growth factor beta (TGF-β) is a cytokine that has been assigned a key role in epithelial
      repair. Injury to the liver elicits a rapid increase in its expression. HCV -infected
      hepatocytes produce (TGF-β) which may stimulate T-regulatory cells.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>assess serum level of interleukin-6 and transforming growth factor beta before intervention and after intervention with sofosbuvir and daclatasvir.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean difference in level of interleukin-6 and transforming growth factor beta after treatment</measure>
    <time_frame>three months from the end of treatment</time_frame>
    <description>serum level of interleukin-6 and transforming growth factor beta will be measured before and after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>group1 (naive)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group2 (sustained responder)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir and daclatasvir</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>group2 (sustained responder)</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 70 years.

          -  HCV RNA positivity .

          -  Any Body Mass Index(BMI).

          -  Treatment-naive or treatment experienced.

          -  all fibrosis stages.

        Exclusion criteria:

          -  Direct serum bilirubin greater than 2 mg/dl.

          -  Serum albumin less than 2.8 g/dl.

          -  International normalization ratio (INR) greater than or equal to 1.7

          -  Platelet count less than 50 000/mm3.

          -  Ascites or history of ascites.

          -  Hepatic encephalopathy or history of hepatic encephalopathy.

          -  Hepatocellular carcinoma.

          -  Serum creatinine greater than 2.5 mg/dl .

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hayam hamdy, master deree</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of medicine,medical microbiology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salwa Sayed Ahmed, proffessor</last_name>
    <phone>01013318344</phone>
    <email>salwaegy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliaa Mahmoud Ali, lecturer</last_name>
    <phone>01006199196</phone>
    <email>aliaaghandour@yahoo.com</email>
  </overall_contact_backup>
  <link>
    <url>https://scholar.google.com/scholar</url>
    <description>related info</description>
  </link>
  <reference>
    <citation>Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res. 2001 Feb;19(2):170-179.</citation>
    <PMID>11164741</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218. Erratum in: N Engl J Med. 2014 Apr 10;370(15):1469.</citation>
    <PMID>24428467</PMID>
  </reference>
  <reference>
    <citation>Baskic D, Vukovic VR, Popovic S, Djurdjevic P, Zaric M, Nikolic I, Zelen I, Mitrovic M, Avramovic D, Mijailovic Z. Cytokine profile in chronic hepatitis C: An observation. Cytokine. 2017 Aug;96:185-188. doi: 10.1016/j.cyto.2017.04.008. Epub 2017 Apr 21.</citation>
    <PMID>28433893</PMID>
  </reference>
  <reference>
    <citation>Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621-36. Review.</citation>
    <PMID>1689567</PMID>
  </reference>
  <reference>
    <citation>Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M; Ochanomizu-Liver Conference Study Group. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Antivir Ther. 2011;16(7):1081-91. doi: 10.3851/IMP1864. Erratum in: Antivir Ther. 2011;16(7):1137-8.</citation>
    <PMID>22024524</PMID>
  </reference>
  <reference>
    <citation>Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest. 1995 Jul;96(1):447-55.</citation>
    <PMID>7615817</PMID>
  </reference>
  <reference>
    <citation>Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm. 2012;2012:949157. doi: 10.1155/2012/949157. Epub 2012 Aug 9. Review.</citation>
    <PMID>22933833</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hayam Hamdy Mahmoud</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <keyword>hepatitis C virus therapy</keyword>
  <keyword>interleukin-6</keyword>
  <keyword>transforming growth factor -beta</keyword>
  <keyword>sustained virological response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Serum concentrations of(IL-6 and TGF-β) will be measured before treatment and after three months from the end of the course of treatment with sofosbuvir 400 mg once daily plus daclatasvir 60 mg for three months using a commercially available Quanti kine ELISA (Enzyme linked Immune sorbent Assay ).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

